Pruritus as a Paraneoplastic Symptom of Thymoma
Sukhmani K. Padda(Stanford University), Heather A. Wakelee(Palo Alto Institute), Alison J. Holmes Tisch(Stanford Health Care), Joel W. Neal(Stanford Medicine), Judy Y. Pagtama(Stanford Health Care), Russell W. Hardy(Mendocino Community Health Clinic), Bernice Y. Kwong(Stanford University), Jonathan W. Riess(University of California Davis Medical Center), Joseph B. Shrager(Stanford Medicine), Ying Liang(Nanjing Agricultural University), Erich Schwartz(Stanford Medicine), Billy W. Loo(Princess Margaret Cancer Centre)
Cited by 2
Related Papers
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k